Pan-EU marketing authorization is all but guaranteed for the seven products that this week received the thumbs up from the European Medicines Agency’s key scientific committee, the CHMP.
The initial marketing authorization applications (MAAs) that received a positive opinion from the CHMP included an orphan-designated advanced therapy medicinal...








